Zheng M, Chen F, Li K, Reja R, Haeffner F, Gao J
J Am Chem Soc. 2022; 144(34):15885-15893.
PMID: 35976695
PMC: 9440474.
DOI: 10.1021/jacs.2c07375.
Zhao S, Su X, Pan R, Lu L, Zheng G, Zou S
BMC Genomics. 2022; 23(1):162.
PMID: 35216548
PMC: 8876555.
DOI: 10.1186/s12864-022-08399-7.
Wang Y, Zhang S, Mu S, Zhang B, Ma S
Nan Fang Yi Ke Da Xue Xue Bao. 2018; 38(8):956-961.
PMID: 30187867
PMC: 6744049.
DOI: 10.3969/j.issn.1673-4254.2018.08.09.
Haq S, Ramakrishna S
Open Biol. 2017; 7(6).
PMID: 28659380
PMC: 5493773.
DOI: 10.1098/rsob.170016.
Sun W, Zhang J, An N, Shen M, Huang Z, Li X
J Int Med Res. 2017; 44(6):1462-1473.
PMID: 28322099
PMC: 5536756.
DOI: 10.1177/0300060516664820.
The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways.
Dwane L, Gallagher W, Chonghaile T, OConnor D
J Biol Chem. 2017; 292(9):3543-3551.
PMID: 28154183
PMC: 5339741.
DOI: 10.1074/jbc.R116.755694.
Targeting biomolecules with reversible covalent chemistry.
Bandyopadhyay A, Gao J
Curr Opin Chem Biol. 2016; 34:110-116.
PMID: 27599186
PMC: 5107367.
DOI: 10.1016/j.cbpa.2016.08.011.
Deubiquitinases and cancer: A snapshot.
Singh N, Singh A
Crit Rev Oncol Hematol. 2016; 103:22-6.
PMID: 27211605
PMC: 7128910.
DOI: 10.1016/j.critrevonc.2016.04.018.
Deubiquitinases and the new therapeutic opportunities offered to cancer.
Pfoh R, Lacdao I, Saridakis V
Endocr Relat Cancer. 2015; 22(1):T35-54.
PMID: 25605410
PMC: 4304536.
DOI: 10.1530/ERC-14-0516.
Bortezomib treatment causes long-term testicular dysfunction in young male mice.
Hou M, Eriksson E, Svechnikov K, Jahnukainen K, Soder O, Meinhardt A
Mol Cancer. 2014; 13:155.
PMID: 24950741
PMC: 4074580.
DOI: 10.1186/1476-4598-13-155.
K63-linked ubiquitination in kinase activation and cancer.
Wang G, Gao Y, Li L, Jin G, Cai Z, Chao J
Front Oncol. 2012; 2:5.
PMID: 22649774
PMC: 3355940.
DOI: 10.3389/fonc.2012.00005.
Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis.
Oliva J, French S, Li J, Bardag-Gorce F
Exp Mol Pathol. 2012; 93(1):26-34.
PMID: 22445925
PMC: 4197193.
DOI: 10.1016/j.yexmp.2012.03.006.
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
Lieu C, Chow L, Pierson A, Eckhardt S, OBryant C, Morrow M
Invest New Drugs. 2008; 27(1):53-62.
PMID: 18618082
PMC: 2829404.
DOI: 10.1007/s10637-008-9154-z.
